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ABSTRACT Multidrug resistance (MDR) has emerged in hospitals due to the use of
several agents administered in combination or sequentially to the same individual.
We reported earlier MDR in Candida lusitaniae during therapy with amphotericin B
(AmB), azoles, and candins. Here, we used comparative genomic approaches be-
tween the initial susceptible isolate and 4 other isolates with different MDR proﬁles.
From a total of 18 nonsynonymous single nucleotide polymorphisms (NSS) in ge-
nome comparisons with the initial isolate, six could be associated with MDR. One of
the single nucleotide polymorphisms (SNPs) occurred in a putative transcriptional
activator (MRR1) resulting in a V668G substitution in isolates resistant to azoles and
5-ﬂuorocytosine (5-FC). We demonstrated by genome editing that MRR1 acted by
upregulation of MFS7 (a multidrug transporter) in the presence of the V668G substi-
tution. MFS7 itself mediated not only azole resistance but also 5-FC resistance, which
represents a novel resistance mechanism for this drug class. Three other distinct NSS
occurred in FKS1 (a glucan synthase gene that is targeted by candins) in three
candin-resistant isolates. Last, two other NSS in ERG3 and ERG4 (ergosterol biosyn-
thesis) resulting in nonsense mutations were revealed in AmB-resistant isolates, one
of which accumulated the two ERG NSS. AmB-resistant isolates lacked ergosterol and
exhibited sterol proﬁles, consistent with ERG3 and ERG4 defects. In conclusion, this
genome analysis combined with genetics and metabolomics helped decipher the re-
sistance proﬁles identiﬁed in this clinical case. MDR isolates accumulated six differ-
ent mutations conferring resistance to all antifungal agents used in medicine. This
case study illustrates the capacity of C. lusitaniae to rapidly adapt under drug pres-
sure within the host.
IMPORTANCE Antifungal resistance is an inevitable phenomenon when fungal patho-
gens are exposed to antifungal drugs. These drugs can be grouped in four distinct
classes (azoles, candins, polyenes, and pyrimidine analogs) and are used in different
clinical settings. Failures in therapy implicate the sequential or combined use of
these different drug classes, which can result in some cases in the development of
multidrug resistance (MDR). MDR is particularly challenging in the clinic since it dras-
tically reduces possible treatment alternatives. In this study, we report the rapid de-
velopment of MDR in Candida lusitaniae in a patient, which became resistant to all
known antifungal agents used until now in medicine. To understand how MDR de-
veloped in C. lusitaniae, whole-genome sequencing followed by comparative ge-
nome analysis was undertaken in sequential MDR isolates. This helped to detect all
speciﬁc mutations linked to drug resistance and explained the different MDR pat-
terns exhibited by the clinical isolates.
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Candida (teleomorph Clavispora) lusitaniae is a ubiquitous ascomycetous yeast thatcan be recovered from soils and water but can survive in different hosts (birds and
mammals). It is known as an opportunistic haploid yeast and is the cause of infrequent
candidemia (1). Mortality due to C. lusitaniae fungemia varies extensively (5% to 50%)
and has often been associated with resistance to amphotericin B (AmB) (2). Even if C.
lusitaniae is considered susceptible to most systemic antifungal agents, several reports
have documented the development of antifungal resistance. Usually, antifungal resis-
tance is restricted to a single agent. For example, Desnos-Ollivier et al. (3) reported
candin resistance in C. lusitaniae from a patient treated with caspofungin over 11 to
17 days. Resistance was associated with a missense mutation (S645F) in the FKS1 gene
encoding 1,3--glucan synthase, the target of candins in several fungal species.
5-Fluorocytosine (5-FC) resistance has also been described in C. lusitaniae and is
associated with defects in cytosine permease (4). Recently, C. lusitaniae resistance to
ﬂuconazole (FLC) was reported in the lungs of cystic ﬁbrosis patients, even in the
absence of a speciﬁc treatment with this drug (5). Simultaneous resistance to AmB and
FLC was described in a patient treated intermittently with the two agents (6). We
reported that C. lusitaniae can develop multidrug resistance (MDR), which is understood
as resistance to at least 2 different drug classes. MDR occurred in 4 distinct C. lusitaniae
isolates recovered from a patient treated sequentially with different antifungal drugs,
including azoles, AmB, and candins (7). Antifungal pressure selected distinct MDR
proﬁles that were corresponding to the administered antifungals. The systemic sequen-
tial isolates that were obtained from the treated patient were shown to be related to
each other, suggesting that they had a common ancestor. We undertook earlier the
identiﬁcation of mutations associated with these drug resistance patterns (7), and only
three separate mutations in FKS1 resulting in candin resistance were identiﬁed. Here,
we applied whole-genome sequencing approaches in sequential isolates of the treated
patient and compared them with the most susceptible isolate that was recovered at
early stages of therapy. Genome comparisons revealed several genome alterations
explaining the different antifungal resistance proﬁles of the clinical strains and genetic
approaches conﬁrmed their roles in antifungal resistance.
RESULTS
C. lusitaniae genomes. We determined earlier that the C. lusitaniae sequential
isolates (named P1 to P5) recovered from the treated patient were related to each other
using restriction sites polymorphism approaches. Isolate P1 was the earliest but still
drug-susceptible isolate, while the others (P2 to P5) exhibited MDR (7). To enable
complete comparisons between these strains, we carried out their genome sequencing
using PacBio technology to produce large telomere-to-telomere assemblies. Five inde-
pendent assemblies were obtained with the ﬁve isolates containing each eight major
contigs (smaller contigs corresponding to mitochondrial genomes were ignored). These
8 major contigs were likely to correspond to the eight suggested chromosomes of C.
lusitaniae previously described either by supercontig assemblies of C. lusitaniae ATCC
42720 (8) or by chromosome separation from electrophoresis (9) and centromere
mapping (10). These PacBio contigs were designated Chr 1 to Chr 8 and were sorted by
their sizes (see Table S2 in the supplemental material). We ﬁrst compared the genomes
of strain P1 with ATCC 42720 by whole-genome alignments. Several chromosome
rearrangements were observed between the two genomes (Fig. 1A) but principally
occurring at chromosome ends between Chr 2 and Chr 6 and between Chr 3 and Chr
4. Genome alignments between isolates P1 to P5 did not reveal major rearrangements,
except for a terminal chromosome fragment of Chr 6, which was positioned at the
opposite chromosome ends in isolates P2 and P4 (Fig. 1B). In addition, P2 and P5
isolates exhibited a sequence gap at the left side of Chr 4 (Fig. 1B), which was the result
of a 30-kb fragment duplication in isolates P1, P3, and P4 (see below).
To allow further genome comparisons, genome data of isolate P1 were next
subjected to gene annotations (see Materials and Methods). This annotation served as
a basis for P2 to P5 genome annotations. The genome characteristics of P1 to P5 are
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FIG 1 Whole-genome alignments. At the top is shown the alignment between ATCC 42720 and isolate P1, and the rows below that show
the alignment between isolates P1 to P5. Alignments were obtained using Mauve (version 2015-02-25), with default parameters, and the
aligner software Muscle 3.6. Vertical red bars indicate separations between the 8 chromosomes. Colored crossed lines between
chromosomes of individual isolates indicate major translocations. Isolate designations are given both as the laboratory collection name and
as earlier published (7) (in parentheses). Color intensities between chromosomes indicate SNP densities between comparisons.
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supplied in Table 1. The number of detected coding sequences (CDS) were ranging
from 5,662 to 5,684 in the P1 to P5 genomes. These numbers lie within ranges
estimated in genomes of ATCC 42720 and CBS 6936 (Table 1). The genome of CBS 6936
was recently reported but did not reach the level of whole-chromosome assemblies
(11). Given that the P1 and ATCC 42720 genomes were chromosome assemblies, these
two genomes were systematically compared for the occurrence of single nucleotide
polymorphisms (SNPs) resulting in synonymous and nonsynonymous changes in the
encoded proteins (Files S1 and S2). Our data suggested the existence of 83,225 SNPs
between the CDS of these two genomes. The count of non-CDS SNPs was up to 118,174
between the two strains, which results in an SNP density of about 1 SNP per 60 bp. This
density is higher than that observed between Candida isolates of the same species (8).
A density plot of the detected SNPs along the chromosomes revealed regions of high
SNP densities separated by stretches of low densities which are indicative of recombi-
nation (Fig. S1). C. lusitaniae is one of the few Candida spp. that is able to undergo
mating and meiosis; therefore, it can be anticipated that recombination events could
be traced to some extent (12). Similar conclusions deduced from SNP density plots were
drawn by genome comparisons of C. glabrata genomes (13). P1 is of the alpha mating
type, which is prevalent in this species (14); thus, mating may have occurred at some
point during the evolution of this strain.
A few other characteristics were observed in the genomes of P1 to P5. As mentioned
above, a 30-kb region in the Chr 4 in P1, P3, and P4 was duplicated compared to P2 and
P5. This region contains 13 CDS and among them a putative agglutinin of 2,633 amino
acids similar to Als2 from Candida albicans. The signiﬁcance of this duplication remains
unclear. In addition, the P1 to P5 isolates each contain 15 separate retrotransposon-like
elements divided into 4 different groups, some of which are ﬂanked by nucleotide
repeats referred to as long terminal repeats (LTRs) (File S3). So far, the presence of
retrotransposons has not been ﬁrmly reported in this species. Last, we observed the
expansion of speciﬁc protein types in each of these isolates. For example, seven distinct
proteins similar to the NADPH-dependent methylglyoxal reductase GRP2 from C. albi-
cans were detected (File S3). GRP2 in C. albicans was shown to be involved in oxidative
stress response (15) and is coregulated with other azole-responsive genes (16). The C.
lusitaniae GRP2-like genes in P1 to P5 exhibit 94 to 58% similarity with each other. So
far, no equivalent of gene family expansion in this type of genes was reported in other
Candida species.
Comparative analysis between the P1 to P5 genomes. In order to identify muta-
tions associated with drug resistance in the sequenced C. lusitaniae genomes, all ﬁve
genomes were aligned, and nucleotide differences in coding and noncoding regions
were recorded, taking isolate P1 as a reference (see Materials and Methods). We showed
earlier that isolate P1 was likely to be the parent of all subsequently isolated C.
lusitaniae samples from the treated patient (isolates P2 to P5). Table 2 summarizes the
occurrence of nucleotide changes existing between isolates P2 to P5, taking P1 as a
genome reference. In general, one can observe a low level of variation between the
TABLE 1 Genome characteristics of C. lusitaniae isolates
Isolatea
No. of:
Reference
or sourceCDS Genes tRNA rRNA
DSY4606 (P1) 5,676 5,882 197 9 This study
DSY4590 (P2) 5,662 5,869 196 11 This study
DSY4593 (P3) 5,684 5,892 198 10 This study
DSY4661 (P4) 5,679 5,886 197 10 This study
DSY4662 (P5) 5,676 5,883 197 10 This study
ATCC 42720 5,936 6,154 217 NAb 8
CBS 6936 5,539 5,740 197 4 11
aIsolate designations are given both as the laboratory collection name and as published previously in
parentheses (7).
bNA, not available.
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genomes, even if yeast samples were recovered within a 5-month period. A total of 18
nonsynonymous SNPs were observed, among which 13 were unique. We counted 166
SNPs/indels in intergenic sequences between the isolates and 14 other indels in open
reading frames (ORFs), some of them (ﬁve) causing unique frameshifts and CDS truncations
(File S4).
Table 3 includes the 25 different ORFs of isolates P2 to P5 that differ from isolate P1.
Two in-frame insertions occurred in two proteins similar to transcription factors (CZF1
and SPT4) in isolates P3 and P5. These insertions could potentially exert positive or
negative effects on the functions of these factors, which remains to be addressed. Other
insertions occurred in isolates P2, P4, and P5 in proteins similar to those encoded by
BPH1 (a protein playing a role in protein sorting), BNR1 (cytoskeleton protein), CBP1
(corticosteroid-binding protein), and to a protein with unknown function (similar to
CLUG_03676 from C. lusitaniae ATCC 42720). Six frameshift mutations occurred in these
genome comparisons. Interestingly, two of them were proteins with potential functions
in cell wall biogenesis. The ﬁrst one was a frameshift mutation in EJF17_2079 (isolate
P4) with similarity to UTR2 (extracellular glycosidase), resulting in a truncation of the 26
amino acids of the full protein. The signiﬁcance of this alteration is unknown; however,
the C-terminal end of Utr2p contains a signal sequence important for glycosylphos-
phatidylinositol (GPI) anchoring of the protein. Therefore, one can speculate some
functional consequence of this protein truncation in isolate P4. The second one was a
frameshift mutation in EJF15_20956 and EJF17_20956 from isolates P3 and P4 with
similarity to GAS4 (a 1,3-beta-glucanosyltransferase). This mutation also results in a
truncation of the full protein at the C terminus but of only three amino acids. Gas4p
contains also a C-terminal signal sequence important for GPI anchoring of the protein.
This short truncation may have limited impact on protein function; however, this needs
still further veriﬁcation. The four other frameshift mutations occurred in ORFs with
other functions in P2 to P5 isolates, all resulting in protein truncations. It is difﬁcult to
predict to which extent these truncations could affect the current phenotypic charac-
terization of the recovered isolates.
With regard to amino acid substitutions detected in the genome comparisons, we
ﬁrst observed changes in four ORFs, including EJF15_30508 (similar to OPT2, an
oligopeptide transporter), EJF15_30569 (similar to MSH2, a DNA mismatch repair gene),
EJF15_30782 (similar to a 60S ribosomal protein), EJF15_50669 (similar to the hypo-
thetical protein CLUG_04164 from C. lusitaniae ATCC 42720), and EJF18_60098 (similar
to CBP1, a corticosteroid-binding protein gene). Out of these, the change V186G in
EJF15_30569 (similar to MSH2) from isolate P3 if of potential interest. Yeast MSH2 is part
of a complex involved in DNA repair, and MSH2 mutations were shown to contribute
to increasing mutation rates in several fungal species (17, 18). The V186G substitution
in EJF15_30569 lies near a domain referred to as the connector domain that is
important for the function of Msh2p (19). It is therefore possible that the V186G
substitution from isolate P3 affects Msh2p function and consequently the frequency at
which mutations can occur in isolate P3 compared to P1.
TABLE 2 Occurrence of nucleotide changes in isolates P2 to P5 compared to P1
Contig or
total
No. of changes by isolate for:
Nonsynonymous SNPs (n  18) Intergenic SNPs/indels (n  166) ORF indels/frameshifts (n  14)
P2 P3 P4 P5 P2 P3 P4 P5 P2 P3 P4 P5
Chr 1 1 2 2 1 9 6 6 6 1 0 1 1
Chr 2 2 0 1 2 9 5 6 3 0 1 2 1
Chr 3 0 3 0 0 10 5 5 6 0 1 0 0
Chr 4 0 0 0 0 15 11 8 9 0 1 2 0
Chr 5 0 1 0 0 5 4 4 3 0 1 0 0
Chr 6 0 0 0 3 2 2 2 1 0 0 1 1
Chr 7 0 0 0 0 3 3 2 2 0 0 0 0
Chr 8 0 0 0 0 6 4 2 2 0 0 0 0
Total 3 6 3 6 59 40 35 32 1 4 6 3
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While inspecting these data from the perspective of antifungal drug resistance,
mutations in several genes associated with the speciﬁc drug resistance proﬁles of P2 to
P5 isolates could be highlighted and are summarized below.
(i) V668G in EJF15_10551 and EJF17_10551 from isolates P3 and P4. EJF15_10551
and EJF17_10551 encode a protein similar to MRR1_CANAL (multidrug resistance
regulator 1 of C. albicans). In C. albicans, this protein is known as a regulator of MDR1,
a major facilitator efﬂux transporter that mediates FLC resistance (20). Gain-of-function
(GOF) mutations in MRR1 result in strong upregulation of this transporter and, conse-
quently, azole resistance. MFS7 (a homolog of MDR1 in C. lusitaniae) was previously
reported to be upregulated in isolates P3 and P4 compared to P1 (7). We therefore
propose that the V668G substitution in EJF15_10551 and EJF17_10551 (now referred to
as MRR1) is a GOF mutation that mediates MFS7 upregulation in P3 and P4.
(ii) S638Y, S631Y, and S638P in EJF17_20482, EJF16_20482, and EJF18_20482
from P2, P4, and P5. EJF17_20482, EJF16_20482, and EJF18_20482 encode proteins
similar to FKS1_YEAST (1,3--glucan synthase). Fks1p is a 1,3--glucan synthase, a
critical enzyme in the biosynthesis of 1,3--glucans in fungi. It is also the target of
candins (21). We reported earlier the presence of these distinct mutations in C.
lusitaniae isolates P2, P4, and P5 and showed that they were causing candin resistance
but using Saccharomyces cerevisiae as a surrogate system (7). The current sequencing
TABLE 3 ORF alterations in isolates P1 to P5 compared to P1
P2 to P4 altered
locus/loci Isolate(s) Gene similaritya Description Amino acid changeb Protein effect
CDS codon
no.c
EJF18_20133 P2, P5 ERG4_YEAST Delta[24(24(1))]-sterol reductase S412¡* Truncation 412
EJF18_60340 P5 ERG3_CANAX Delta(7)-sterol-5(6)-desaturase Q308¡* Truncation 308
EJF15_10551,
EJF17_10551
P3, P4 MRR1_CANAL Multidrug resistance regulator 1 V¡G Substitution 668
EJF15_10714,
EJF17_10714,
EJF18_10714
P3, P4,
P5, P2
BSC5_YEAST Bypass of stop codon protein 5 F¡L Substitution 447
EJF17_20482 P2 FKS1_YEAST 1,3--glucan synthase
component FKS1
S¡Y Substitution 638
EJF16_20482 P4 FKS1_YEAST 1,3--glucan synthase
component FKS1
S¡Y Substitution 631
EJF18_20482 P5 FKS1_YEAST 1,3--glucan synthase
component FKS1
S¡P Substitution 638
EJF15_30508 P3 OPT2_YEAST Oligopeptide transporter 2 P¡L Substitution 895
EJF15_30569 P3 MSH2_YEAST DNA mismatch repair MSH2 V¡G Substitution 186
EJF15_30782 P3 CLUG_02496 60S ribosomal protein E¡K Substitution 206
EJF15_50669 P3 CLUG_04164 CLUG_04164 Clavispora
lusitaniae ATCC 42720
P¡S Substitution 25
EJF18_60098 P5 CBP1_CANAL Corticosteroid-binding protein A¡K Substitution 531
EJF18_60098 P5 CBP1_CANAL Corticosteroid-binding protein K¡A Substitution 536
EJF18_20361 P5 STP4_CANAL Transcriptional regulator STP4 QF¡QFQYPGGTKKSQR
NQVAGCCRLCQAQF
Insertion 306
EJF15_30283 P3 CZF1_CANAL Zinc cluster transcription factor
CZF1
N¡NN Insertion 150
EJF17_40359 P4 BPH1_YEAST Beige protein 1 EE¡E Deletion 1181
EJF17_40476 P4 CLUG_03676 CLUG_03676 Clavispora
lusitaniae ATCC 42720
Q¡QQ Insertion 141
EJF16_40795 P2 BNR1_CANAL Formin BNR1 HEAKD¡H Deletion 1777
EJF18_60098 P5 CBP1_CANAL Corticosteroid-binding protein D¡DKEDRD Insertion 540
EJF17_10341 P4 YD338C_YEAST Uncharacterized transporter
YDR338C
S39 Frameshift 39
EJF18_10886,
EJF16_10886
P5, P2 CLUG_00859 CLUG_00859 Clavispora
lusitaniae ATCC 42720
G89 Frameshift 89
EJF17_20798 P4 UTR2_CANAL Extracellular glycosidase UTR2 V401 Frameshift 401
EJF15_20956,
EJF17_20956
P3, P4 GAS4_YEAST 1,3--glucanosyltransferase
GAS4
P175 Frameshift 175
EJF15_50735 P3 LGUL_YEAST Lactoylglutathione lyase Y268 Frameshift 268
EJF17_60452 P4 APE2_CANAL Aminopeptidase 2 L725 Frameshift 725
aSimilarities to proteins of the UniProt database are given. The UniProt database contains protein names listing the encoding gene names followed by sufﬁxes
indicating the species origin (CANAL and CANAX, Candida albicans; YEAST, Saccharomyces cerevisiae). Some matches with C. lusitaniae ATCC 42720 are given with the
original nomenclature.
b*, conversion of the codon into a stop codon. For single amino acids, the position of the last amino acid of the coding sequence after insertion/deletion of
nucleotides is indicated.
cCDS positions at which the amino acid changes occur.
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data conﬁrm these different mutations in EJF17_20482, EJF16_20482, and EJF18_20482
(now referred as to FKS1) that were previously deduced from speciﬁc Sanger sequenc-
ing reactions.
(iii) Truncations in EJF18_20133 and EJF18_60340 from isolates P2 and P5.
EJF18_20133 and EJF18_60340 encode proteins similar to ERG4_YEAST [delta(24(24
(1)))-sterol reductase] and ERG3_CANAX [delta(7)-sterol-5(6)-desaturase], respectively.
In isolate P2, EJF18_20133 (further referred as to ERG4) underwent a nucleotide change
(C to A) converting the TCG codon (Ser412) into a stop codon (TAG; erg4amber), thus
truncating the full Erg4p by 49 amino acids. While the same mutation was detected in
isolate P5, another distinct mutation in EJF18_60340 (now referred as to ERG3) was
revealed in the same isolate. ERG3 underwent a nucleotide change (C to T) converting
the CAA codon (Gln308) into a stop codon (TAA; erg3ochre), thus truncating the full Erg3p
by 59 amino acids. Both P2 and P5 were reported to be resistant to AmB (7). Both ERG4
and ERG3 truncations may have resulted in altered sterol composition in these isolates,
thus leading to the depletion of ergosterol, which is a known factor mediating AmB
resistance (22).
Taking these comparative descriptions together, we summarized the potential
associations existing between the isolate genotypes and the reported antifungal drug
resistance proﬁles in Fig. 2, considering only single-amino-acid substitutions for com-
parisons. Isolate P1 was previously shown as the earliest yeast recovered from the
patient at early stages of antifungal treatment, and isolates P2 to P5 were timely
sequential isolates. Given the high nucleotide resemblance between the isolates and
that isolates P2 to P5 exhibit the same SNP as P1 (BSC5 F447L), the data conﬁrm that
P1 is the ancestor of P2 to P5. However, it is less likely that each isolate represents a
progeny from the other. This conclusion is supported by the different SNP proﬁles
found in the isolates (Table 3). Interestingly, P3 and P4 share the same substitution in
MRR1 (V668G) and the same frameshift mutation in EJF15_20956 and EJF17_20956
(GAS4), thus pointing to a common ancestor. P2 and P5 also share SNPs leading to the
same truncation in ERG4 (S412*) and the same frameshift mutation in EJF14_10886,
which suggests that the two isolates originated from a common ancestor. However,
each of these isolates also contains speciﬁc other SNPs, indicating that they evolved in
individual directions. Fitness costs could have been a consequence of the different
FIG 2 Overview of C. lusitaniae isolates phenotypes and genotypes. A timeline scale indicates the drug
regimen administered to the patient, as reported earlier (7). Vertical black bars highlight the timing of
sampling. Each fungal isolate (P1 to P5) is documented for drug susceptibilities and the occurrence of
SNPs in CDS and origin of sampling. NA, not available; VOR, voriconazole; CAS, caspofungin; FLC,
ﬂuconazole, AMB, amphotericin B. Wild-type drug MICs are boxed in yellow, while MICs indicating
resistance are boxed in red. Only SNP variants in coding regions are reported here. Red-labeled genes
and their SNPs indicate associations to drug resistance. S412* and Q308* signify changes of serine and
glutamine, respectively, into a stop codon.
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mutations occurring during the evolution of the clinical strains. It cannot be excluded
that these possible ﬁtness defects were compensated for by distinct mutations in
isolates P2 to P5 listed in Table 3. To summarize, besides the already-known reported
FKS1 mutations, we identiﬁed here three novel mutations, V668G in MRR1, possibly
mediating FLC resistance; S412* in ERG4; and Q308* in ERG3, which might be respon-
sible for AmB resistance.
Role of MRR1 in FLC resistance. Our data suggested that MRR1 (EJF14_10551)
could be involved in FLC resistance in C. lusitaniae due to the occurrence of a V668G
substitution. To address this question, we ﬁrst undertook an RNA sequencing (RNA-seq)
analysis in isolates P3 and P4 grown under normal conditions and compared the data
with P1 (see Materials and Methods). According to our selection (1.5-fold expression
change compared to P1; File S4), there were 54 and 30 genes up- and downregulated,
respectively, in P4. In a comparison of P3 with P1, 16 genes were inversely regulated,
keeping this threshold. Using a Gene Ontology (GO) terms enrichment analysis based
on gene annotations of C. albicans homologs, signiﬁcant enrichment of functions
related to azole transport and oxidoreductase activity were detected among commonly
upregulated genes in P3 and P4 (File S4). Highly upregulated genes (215- to 57-fold in
P4 and P3 versus P1) involved in these biological processes include alcohol dehydro-
genases (EJF14_60130 and EJF14_40004, similar to ADH6 and ADH7) and a NADPH-
dependent methylglyoxal reductase (EJF14_20072, similar to GRP2). MFS7 was among
these highly upregulated genes (17- and 15-fold upregulation in P4 and P3 versus P1)
in isolates containing the MRR1 V668G substitution. MRR1 itself was signiﬁcantly
upregulated in P3/P4 isolates (1.5-fold versus P1). These expression proﬁles are
consistent with the imprint of MRR1 GOF mutations in C. albicans on the transcriptome
of this species (20). We therefore suggest that the C. lusitaniae MRR1 V668G substitution
is a GOF mutation which impacts on the expression of different target genes, among
them MFS7.
In order to further address the role of MRR1 and MFS7 in the drug resistance proﬁles,
we ﬁrst attempted gene knockout approaches. Preliminary results using homologous
recombination with a dominant marker (SAT1) ﬂanked by MFS7 and MRR1 5= and 3=
regions proved to be inefﬁcient. We therefore used a CRISPR-Cas9 approach with guide
RNAs speciﬁc for MFS7 and MRR1 using in vitro-reconstituted RNA-protein complexes
(RNPs) and repair fragments with the dominant marker by NAT1 ﬂanked by MFS7 and
MRR1 5= and 3= regions (see Materials and Methods). CRISPR-Cas9 and corresponding
repair fragments were used in isolates P1 and P3, and the expected mutants were
veriﬁed as described (see Materials and Methods). Figure 3A shows that the deletion of
both MFS7 and MRR1 in the background of azole-susceptible isolate P1 did not
signiﬁcantly alter FLC susceptibility assessed by serial dilution assays and MIC measure-
ments (MIC values ﬂuctuated between 1 and 0.25 g/ml FLC for all P1 and P1-derived
mutants; see File S6 for full MIC data). On the contrary, deletion of both MFS7 and MRR1
in the background of the azole-resistant isolate P3 signiﬁcantly altered azole suscep-
tibility, as follows: while the initial isolate P3 exhibited a MIC value of 64 g/ml FLC,
deletion of MRR1 resulted in a 64-fold MIC decrease (FLC MIC, 1 g/ml; File S6), and the
deletion of MFS7 resulted in a 8-fold MIC decrease (FLC MIC, 8 g/ml; File S6). We
addressed the effect of MRR1 deletion on MFS7 expression by quantitative PCR (qPCR)
and, while MFS7 expression was increased by 28-fold between the isolates P1 and P3,
it was decreased by 14-fold in the absence of MRR1 between P3 and its MRR1-derived
mutant (Fig. 4A). These ﬁndings indicate that the MRR1 allele of P3 containing the
V668G substitution mediates MFS7 regulation in C. lusitaniae.
To demonstrate a genetic link between the presence of a MRR1 GOF mutation and
azole resistance, we next constructed revertants from a MRR1 mutant in which the
MRR1 alleles from P1 (wild-type allele) and P3 (GOF allele) were reintroduced. This
experiment required the recycling of the NAT1 dominant marker; thus, a MAL2-
dependent ﬂipper system permitting excision of the NAT1 marker was designed, and a
separate MRR1 mutant lacking the selection marker was produced (DSY5416, see
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Materials and Methods). CRISPR-Cas9 combining two guide RNAs targeting ﬂanking
MRR1 regions was used with MRR1 wild-type and GOF alleles on the NAT1 dominant
marker to produce the ﬁnal revertants. Figure 3B shows that the presence of the MRR1
GOF allele alone could restore azole resistance (FLC MIC, 64 g/ml; File S6) and thus
demonstrates the association between the MRR1 GOF mutation V668G and azole
resistance. Consistently, high MFS7 expression was restored from the MRR1 deletion
mutant in the presence of the MRR1 GOF mutation and not with the MRR1 wild-type
allele (Fig. 4B).
FIG 3 MRR1 andMFS7mediate FLC resistance in C. lusitaniae. (A) Tenfold serial dilutions were performed,
starting with an inoculum of about 105 cells. Mutants for MRR1 and MFS7 in P3 correspond to DSY5240
and DSY5242 and in P1 to isolates DSY5246 and DSY5248, respectively. MIC values were obtained by MIC
measurements using the SYO system, as described in Materials and Methods. (B) Reversion of MRR1
deletion. Mutants for MRR1 correspond to DSY5416. Revertants for MRR1 wild-type allele and MRR1 GOF
allele (MRR1V668G) correspond to isolates DSY5437 and DSY5438, respectively (Table S1). The white line
indicates removal of a yeast sample from the original agar plate.
FIG 4 Expression of MFS7 in C. lusitaniae. (A) MFS7 expression in P1 and P3 and derived MRR1 mutants
(DSY5246 and DSY5240, respectively). MFS7 expression fold changes are indicated between speciﬁc
isolates. (B) MFS7 expression in MRR1 revertants (for DSY5437, mrr1Δ::MRR1, and for DSY5438, mrr1Δ::
MRR1V668G) derived from DSY5416 (mrr1Δ::FRT) (Table S1). MFS7 expression was calculated relative to the
initial isolate P1. qPCRs were performed with biological triplicates, as described in Materials and Methods.
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Role of MRR1 in 5-FC resistance. We showed earlier in the C. lusitaniae isolates
recovered from a treated patient that FLC resistance was associated with 5-FC resis-
tance, even if the patient was not exposed to the pyrimidine analog. 5-FC resistance in
C. lusitaniae is mediated by mutations occurring in genes involved in 5-FC transport and
metabolism (FCY1 and FCY2) (23). In other species, such as C. albicans, other genes
(FUR1, encoding uracil phosphoribosyltransferase) contain mutations resulting in 5-FC
resistance (24). None of these genes contained mutations in isolates P2 to P5. This
raised the hypothesis that 5-FC resistance could be mediated by alternative mecha-
nisms, and especially by MFS7 upregulation, since it results in FLC resistance that itself
correlates with 5-FC resistance. We tested this hypothesis by ﬁrst expressing MFS7 in a
heterologous system in which major C. albicans multidrug transporters (CDR1, CDR2,
MDR1, and FLU1) were inactivated (25). We observed by serial dilution spotting assays
(Fig. 5A) that FLC resistance occurred when MFS7 was overexpressed, as did the C.
albicans ABC transporter CDR1, as expected. Interestingly,MFS7 overexpression resulted
in a speciﬁc 5-FC resistance since it was not observed by CDR1 overexpression (Fig. 5A).
We also conﬁrmed by green ﬂuorescent protein (GFP) tagging that MFS7 localized
principally to cell structures in C. albicans believed to be cell membranes (Fig. 5B). These
data suggest that MFS7 is a cell membrane-associated transporter for 5-FC. We took
advantage of MRR1 and MFS7 mutants to address their susceptibility to 5-FC. Figure 6A
shows that the deletion of both genes resulted in a 64-fold decrease in the MIC
compared to that with the parent strain P3. In addition, the reversion of the MRR1
deletion by a MRR1 GOF allele restored 5-FC resistance (Fig. 6B and File S6). Taken
together, our data indicate for the ﬁrst time that MRR1 is responsible for 5-FC resistance
in C. lusitaniae and that this resistance is mediated by MFS7, especially when upregu-
lated. This novel mechanism is likely to explain the cross-resistance between the two
drug classes in C. lusitaniae.
ERG3 and ERG4 loss of functions and AmB resistance of isolates P2 and P5. In
our previous report, the mechanisms behind AmB resistance of isolates P2 and P5
remained puzzling. P2 and P5 isolates exhibited AmB MICs of 1 and 2 g/ml compared
to P1 (MIC, 0.25 g/ml; File S6). Here, we showed by genome comparisons that the two
isolates contained SNPs converting codons of ERG3 and ERG4 into stop codons. P2
exhibited a truncation in Erg4p only, while P5 carried truncations in both Erg4p and
Erg3p. These mutations could result in loss of function and therefore interruption of
ergosterol biosynthesis. Figure 7 shows the sterol biosynthesis pathway and highlights
the position of ERG3 and ERG4 as well as interference of mutations in P2 and P5 in this
FIG 5 MFS7 mediates 5-FC resistance. (A) Tenfold serial dilutions were performed, starting with an
inoculum of about 105 cells at the indicated 5-FC concentration. MFS7 overexpression was obtained by
a CDR1-MFS7 chimeric construct expressed in DSY5170. The control strain is DSY5169 (see Table S1), and
the CDR1 overexpression strain is ANY-MDR1-GFP (CaCDR1) (Table S1). (B) Localization of MFS7-GFP in C.
albicans. Microscopy was performed under normal light with differential interference contrast (DIC)
microscopy and with epiﬂuorescence, as described in Materials and Methods. GFP localization shows the
typical “rim” staining of membrane proteins.
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pathway. A single ERG4 loss-of-function mutation is expected to result in the accumu-
lation of ergosta-5,7,22,24-(28)-tetraenol together with other sterol precursors. The
combined ERG3 and ERG4 loss-of-function mutations are expected to yield ergosta-
7,22,24-(28)-trienol as major by-product. These expectations could be veriﬁed by mass
spectrometry analysis of the sterol fractions of P2 and P5. As shown in Table 4, P2
accumulated ergosta-5,7,22,24-(28)-tetraenol up to 98% in the sterol fraction, while P5
accumulated ergosta-7,22,24-(28)-trienol up to 82% of total sterols with other precur-
FIG 6 MRR1 and MFS7 mediate 5-FC resistance in C. lusitaniae. (A) Tenfold serial dilutions were
performed, starting with an inoculum of about 105 cells. Mutants for MRR1 and MFS7 in P3 correspond
to DSY5240 and DSY5246 and in P1 to isolates DSY5242 and DSY5248, respectively (Table S1). MIC values
were obtained by MIC measurements using the SYO system, as described in Materials and Methods. (B)
Reversion ofMRR1 deletion. Mutants forMRR1 correspond to DSY5416. Revertants for theMRR1 wild-type
allele and MRR1 GOF allele (MRR1V668G) correspond to isolates DSY5437 and DSY5438, respectively
(Table S1).
FIG 7 Sterol biosynthesis pathway and defects of isolates P2 and P5. The pathway includes the steps from the
substrate lanosterol up to the formation of ergosterol (22). Major genes and sterol intermediates are indicated.
ERG3 and ERG4 steps are highlighted, and red circles show the activity on the sterol molecule (saturation/
desaturation). The ERG4 defect in P2 and combined defects in ERG3 and ERG4 are indicated with corresponding
intermediate accumulations (red rectangles).
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sors (fecosterol and episterol) resulting from reactions upstream of ERG3. The other
AmB-susceptible isolates (P1, P3, and P4) exhibited ergosterol as a major sterol com-
ponent (95 to 98% of total sterols). Taken together, these sterol analysis suggest that
the identiﬁed ERG3 and ERG4 mutations result in loss of function of the gene products.
The accumulation of two separate mutations in P5 yields the expected sterol compo-
sition. We believe that the absence of ergosterol in P2 and P5 results in their AmB
resistance, as reported earlier (7). To further address the relationships between phe-
notypes and genotypes in P2 and P5, ERG3 and ERG4 wild-type copies were reintro-
duced in these isolates by a CRISPR-Cas9 approach. Isolate P5 necessitated the resto-
ration of two different wild-type gene copies which could be carried out by the use of
two different positive selection markers (NAT1 and CaHygB). Ergosterol biosynthesis
was restored in P2/P5 revertants with ERG3 and ERG4 wild-type copies (DSY5441 and
DSY5452 in Table 4). As shown in Fig. 8, AmB resistance of P2/P5 was reversed to MIC
levels of the initial P1 isolate when ERG3 and ERG4 wild-type copies were restored in
these isolates (MICs, 0.125 and 0.25 g/ml; File S6). Interestingly, the ERG4 revertant
DSY5444 with the erg3ochre defective allele still exhibits high AmB MIC (1 g/ml), which
is consistent with absence of ergosterol in this isolate and formation of ergosta-7,22-
dienol (Table 4), a known sterol metabolite identiﬁed in erg3 Candida species mutants
(26). The constructed ERG4 and ERG3 revertants, while they exhibited changes in AmB
TABLE 4 Sterol composition of isolates P1 to P5 and derived mutantsa
Sterol metabolite
Sterol content of isolates (% mean  SD)
P1 P2 erg4amber P3 P4
P5 erg4amber
erg3ochre
DSY5441
ERG4b
DSY5444
ERG4 erg3ochre b
DSY5452
ERG4 ERG3b
Ergosta-8,22-dienol 5.8  0.2
Ergosta-5,8,22,24(28)-tetraenol 0.8  0 0.8  0.1 0.7  0.1 0.3  0.0 0.9  0.3
Ergosta-5,8,22-trienol 0.8  0 0.7  0 0.6  0 0.8  0.0
Zymosterol 2.2  0.4 2  0.8 2.1  0.1 1.0  0.2
Ergosterol 95  0.5 95.8  0.5 94.8  0.3 91.3  1.5 0.3  0.1 89.2  0.5
Ergosta-5,7,22,24(28)-tetraenol 98.5  0.8 0  0.1 5.5  0.9 9.9  0.2
Ergosta-8,22,24(28)-trienol 8.4  0.1
Ergosta-7,22-dienol 65.8  3.1
Fecosterol 0.1  0 0.3  0.2 0.8  0.1 0.8  0.4 2.8  0.6
Ergosta-7,22,24(28)-trienol 82.3  0.7 0.6  0.2 11.9  1.1
Ergosta-5,7-dienol 0.7  0.6 0.3  0.1
Episterol 0.1  0.2 0.3  0.2 7.5  1.1 7.1  0.9
Ergosta-7-enol 1.3  0.1
Lanosterol/obtusifoliol 0.4  0.2 0.2  0.2 0.4  0.2 0.2  0.0
4,4-dimethyl-cholesta-8,24-dienol 0.3  0.1
Unknown 0.1  0.1 1.5  1 0.1  0.1 1.1  0.1 2.2  0.2
Total 100 100 100 100 100 100 97.1 100
aPrincipal sterols and linked sterol content values are in bold type.
bThe complete genotypes can be found in Table S1.
FIG 8 ERG3 and ERG4 reversions in isolates P2 and P5. Tenfold serial dilutions were performed, starting
with an inoculum of about 105 cells. MIC values were obtained by MIC measurements using the SYO
system, as described in Materials and Methods. The ERG4 revertants from P2 and P5 are DSY5441
(erg4amber::ERG4::NAT1) and DSY5444 (erg4amber::ERG4::NAT1 erg3ochre), respectively. The ERG4 and ERG3
revertant from P5 is DSY5452 (erg4amber::ERG4::NAT1 erg3ochre::ERG3::CaHygB) (Table S1). Arrows indicate
parental relationships between isolates.
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MIC values, did not show altered MIC values for other antifungal agents (File S6). This
highlights the speciﬁcity of the genetic changes and also demonstrates the genetic
basis of AmB resistance in isolates P2 and P5.
DISCUSSION
In this work, we showed that the use of genome mining approaches were helpful in
the resolution of drug resistance mechanisms in C. lusitaniae. Isolates P1 to P5 were
recovered within a 5-month period, and the exploration of genome data revealed a
limited spectrum of nucleotides changes between the strains within this time lapse. We
obtained ﬁve independent chromosome assemblies using the PacBio technology which
look essentially similar between isolates P1 to P5, thus indicating the robustness of the
assembly approaches. Apart from a speciﬁc region duplication and chromosome rearrange-
ments (Chr 6), only a few nonsynonymous SNPs were identiﬁed (18) in addition to a
higher number of changes in intergenic regions. Comparisons with other available
genomes of C. lusitaniae suggested much higher level of nucleotide divergence. In a
comparison of coding regions alone between the C. lusitaniae strain ATCC 42720 with
P1 to P5, 83,225 SNPs were identiﬁed. This accounts for a large nucleotide divergence
within the same species, a feature also reported in the study of genome comparisons
made in other Candida spp. (27, 28). Recently, a study reported the analysis of 20
different C. lusitaniae isolates from a patient with cystic ﬁbrosis (5). The study reported
404 interisolate SNPs (among which 45% were NSS) and 536 indels in total. In
comparison, we observed less variation between P1 to P5 in the present work.
Additional C. lusitaniae genomes should be analyzed for the further appreciation of
genome divergence within this species.
The primary goal of this study was to perform detailed analysis of genomes between
isolates P1 to P5 in order to identify the molecular basis of antifungal resistance in the
recovered samples. Our data suggest that each isolate originated from the most
susceptible isolate, P1. We showed earlier that the speciﬁc drug resistance proﬁles
followed the drug regimen (7). The SNP proﬁles of each isolate now suggest that each
isolate underwent independent microevolution trajectories within the host under drug
selection. Common SNPs responsible for drug resistance were observed in isolates P3
and P4 (V668G of MRR1) and in isolates P2 and P5 (S412* of ERG4). This raises the
possibility of a closer relationship between these isolate pairs. However, each of the
isolates contains additional SNPs and indels which are against the hypothesis of a close
lineage, i.e., that each of the P4 and P5 isolates are issued from parents P3 and P2,
respectively. Given the number of shared SNPs between the isolates P3/P4 and P2/P5
isolates, it is possible that they originated from common ancestors. More detailed
relationships between isolates could have been revealed with a larger isolate collection,
however, and this is one of the limitations of our study, that the isolate sampling
strategy was not aimed ﬁrst to address isolate diversity.
FLC resistance was earlier correlated with the upregulation of the multidrug trans-
porter MFS7, a close homolog of the C. albicans transporter MDR1. Genome compari-
sons in C. lusitaniae isolates P1 to P5 identiﬁed a SNP in MRR1 leading to a V668G
substitution in P3 and P4. We provided genetic evidence (knockouts and reversion
experiments) to support the idea that the V668G substitution is a GOF mutation which
stimulates MFS7 expression. These data are consistent with a recent study describing
severalMRR1mutations associated with FLC resistance in C. lusitaniae but not including
the V668G GOF mutation (5). This mutation may lead to the upregulation of several
other genes, and this hypothesis was conﬁrmed here by RNA-seq analysis of the P3 and
P4 isolates. Interestingly, our data match well with those comparing an azole-resistant
isolate with an azole-susceptible C. lusitaniae isolate (5). From the 19 identiﬁed regu-
lated genes in this work (5), 12 were corresponding in our data set, and MFS7 (also
called MDR1) was among the upregulated genes in the azole-resistant isolates (File S4).
It was interesting to observe that deletions of MRR1 and MFS7 in P3 resulted in
different FLC MIC values (MICs, 1 g/ml and 8 g/ml, respectively). This underscores
that, in addition to MFS7, MRR1 controls other FLC resistance mediators. One likely
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candidate could be the CDR1 homolog EJF14_30164, which is 2- to 4-fold upregulated
in P3 and P4, respectively, compared to P1 (File S4). CDR1, also known as ABC15 (29),
was shown previously as slightly upregulated in P3 and P4 compared to P1 (7). CDR1
and homologs are known to mediate azole efﬂux and are important contributor of
azole resistance in several fungal pathogens (30). CDR1 may be controlled by MRR1 in
C. lusitaniae. This contrasts with the regulatory properties of MRR1 in C. albicans, which
do not include CDR1 (31). Further work is needed to address this question.
The MRR1 V668G substitution was associated with another phenotype (resistance to
5-FC), and we propose that the multidrug transporter MFS7 (a major facilitator efﬂux
transporter) could mediate this phenotype. The data supporting this conclusion are
based on genetic approaches as well as MFS7 overexpression in C. albicans. Until now,
5-FC resistance in Candida spp. has been looked essentially at the angle of drug import,
and our work provides evidence that drug efﬂux may also be involved. One can also
argue that the known 5-FC import system (such as FCY2) could be regulated in the
presence of the MRR1 V668G mutation, which would result in 5-FC resistance; however,
our RNA-seq data do not support this hypothesis (data not shown). Interestingly, it was
shown in C. lusitaniae by Noël et al. (4) that FLC and 5-FC can exhibit cross-resistance
when the two drugs are combined in vitro; however, the mechanism behind this
observation remained elusive. In this experimental setting, we propose that MFS7 could
have been upregulated in a transient manner by the addition of both drugs in vitro. This
possible elevated expression could be sufﬁcient to result in a cross-resistance pheno-
type. Additional work is warranted to support this hypothesis.
The genome comparisons out of PacBio assemblies identiﬁed the same three
separate FKS1mutations that were earlier reported in isolates P2, P4, and P5 (7). We also
conﬁrmed in our ﬁrst study that the FKS1 amino acid substitutions S638P, S638Y, and
S631Y were causing candin resistance, using S. cerevisiae as a surrogate (7). Recently, it
was reported that S638P substitution could mediate candin resistance in C. lusitaniae.
This was achieved by allelic replacement in this species (32) and thus conﬁrms the
importance of the FKS1 position 638Ser in establishing candin resistance in C. lusitaniae.
The Fks1p position 638Ser lies within a region called hot spot region 1 (HS1) that is
enriched in amino acid substitutions responsible for candin resistance (32). Position
631Ser is the only position that was yet not been conﬁrmed as causing candin resistance
in C. lusitaniae; however, its proximity to HS1 and our own study with S. cerevisiae
makes the S631Y substitution a likely cause of candin resistance.
AmB resistance in fungal pathogens is usually caused by mutations in the ergosterol
biosynthesis pathway (33). C. lusitaniae develops resistance to AmB during infections
and also by inactivation of speciﬁc ERG genes in vitro (34). In this work, we provide
evidence that AmB resistance is mediated by the loss of function of two genes, ERG3
and ERG4. ERG3 loss-of-function mutations have been documented in several fungal
pathogens, all resulting in AmB resistance (26, 35–38). To our knowledge, ERG4 loss-
of-function mutations have not been described so far in fungal pathogens. We show
here that ERG4 loss of function results in the absence of ergosterol, thus contributing
to AmB resistance, as measured earlier (7). A surprising result was the combination of
the two loss-of-function mutations in isolate P5, which was the last recovered isolate
from the treated patient. The accumulation of two different loss-of-function ERG
mutations in the same isolate is unique, to our knowledge, in fungal pathogens. Until
now, the combination of ERG mutations was only known in C. albicans for functional
ERG11 point mutations combined with defects in ERG5 or ERG3 leading to both azole
and AmB resistance (35, 39). Interestingly, isolate P5 exhibits a slightly higher AmB MIC
than does P2 (2 versus 1 g/ml, respectively; File S6), and thus, it is likely that the
accumulation of two ERG mutations conferred enhanced protection against the activity
of AmB in this isolate. Supposing that P2 is the parent of P5, this implies that the ERG3
mutation occurred sequentially after the emergence of the ERG4 mutation; however,
we cannot ﬁrmly conﬁrm this hypothesis. The combination of the loss-of-function
mutations, irrespective of their timely occurrence, rather suggests functional compen-
satory effects. For example, one of the mutations in the ERG genes (i.e., ERG4) could
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have resulted in ﬁtness defects and therefore decreased virulence. We addressed this
hypothesis by testing the virulence of each isolate in the minihost Galleria mellonella.
Our results could not detect signiﬁcant virulence differences between strains (Fig. S2).
The necessity for P5 to carry two independent ERG3 and ERG4 loss of function may be
therefore solely explained by the resulting beneﬁt in AmB resistance.
Taken together, the results of our study highlight that genome comparisons are
highly relevant in the resolution of drug resistance mechanisms. Genome sequencing
is becoming affordable, and several other studies have already taken comparative
genomics as a way to detect antifungal resistance mechanisms (40). Nevertheless, the
relevance of genome alterations needs to be addressed by parallel experimental
approaches that are now greatly facilitated by the development of novel genome
editing technologies (such as the use of CRISPR-Cas9).
MATERIALS AND METHODS
Strains and media. C. lusitaniae and C. albicans isolates were grown in YEPD complete medium (1%
Bacto peptone; Difco Laboratories, Basel, Switzerland), 0.5% yeast extract (Difco), and 2% glucose (Fluka,
Buchs, Switzerland) at 30°C under agitation. The genotypes of all strains constructed are listed in
Table S1. Plasmids were propagated in Escherichia coli DH5 on Luria-Bertani (LB) 2% agar plates at 37°C
overnight (41). LB medium was supplemented with either 100 g/ml ampicillin (AppliChem) or 34 g/ml
chloramphenicol (Fluka) when necessary.
Antifungal susceptibility testing. Antifungal susceptibility testing was carried out using the Sen-
sititre YeastOne (SYO) colorimetric microdilution method and was performed using commercially avail-
able panels (Thermo Fisher Scientiﬁc, Switzerland), according to the manufacturer’s recommendation.
The serial dilution susceptibility method was performed onto agar plates with either YEPD or YNB
minimal medium (0.67% yeast nitrogen base [Difco] with 2% glucose). Yeast cells from an overnight
culture in YEPD medium were diluted to 1.5 107 cells/ml in 1 ml phosphate-buffered saline (PBS;
Bicshel, Interlaken, Switzerland), and 200 l of this solution was transferred to a 96-well ﬂat-bottom plate
(Sigma-Aldrich). Tenfold serial dilutions were performed from 1.5 107 to 1.5 102 cells/ml in PBS. The
cell dilutions were next spotted on plates with a 48-pin replicator (V&P Scientiﬁc, Inc., San Diego, CA,
USA) and the plates incubated at 35°C for 24 to 48 h.
PacBio genome sequencing. In order to produce high-quality genomic DNA from C. lusitaniae
isolates, overnight cultures (5 ml) were grown in YNB minimal medium (0.67% yeast nitrogen base [Difco]
with 2% glucose) at 30°C to obtain 2 108 cells for each strain. DNA isolation followed the instructions
of the Gentra Puregene Yeast/Bact kit (Qiagen), with slight modiﬁcations. First, yeast cell lysis was
performed with Zymolyase 100T (3 g/l end concentration) for 30 min at 37°C. In addition, phenol-
chloroform extractions were carried out after RNase A treatment of precipitated nucleic acids, according
to recommendations issued by Paciﬁc Biosciences (PacBio SampleNet-shared protocol) for the use of
phenol-chloroform-isoamyl alcohol. After ﬁnal precipitation with NH4OAc and several washes with 80%
alcohol, the genomic DNA was dissolved carefully in a small volume of elution buffer (10 mM Tris-HCl [pH
8.5]). Aliquots of 5 g of extracted, high-quality, genomic DNA was diluted to 150 l using elution buffer
at 30 g/l. Long-insert SMRTbell template libraries were prepared (20-kb insert size) according to
PacBio protocols. Each isolate used 2 single-molecule real-time (SMRT) cells, which were sequenced using
P6 polymerase binding and C4 BluePippin sequencing kits with 240-min acquisition time on PacBio RSII
at the Lausanne Genomic Technologies Facility (LGTF) of the University of Lausanne (Unil). De novo
genome assemblies were produced using PacBio’s SMRT Portal (v2.3.0) and the Hierarchical Genome
Assembly Process (HGAP version 3.0), with default settings and a seed read cutoff length of 6,000 bp.
Annotation. For the C. lusitaniae annotation process, we took advantage of available RNA-seq reads
obtained from isolates P1, P3, and P4 isolates (see below). These reads were used to predict and conﬁrm
CDS of the sequenced genomes. Processed reads were aligned against the P1 reference genome
available as a fasta ﬁle from PacBio assemblies (see below), and the resulting alignments were assembled
into potential transcripts using StringTie (v1.3.3) (42). These transcript assemblies were subsequently
used as expressed sequence tag (EST) evidence for assigning the structural annotations to the P1
genome using Work-Queue Maker (WQ-MAKER) (43). The UniProt C. lusitaniae protein data set was
downloaded at https://www.uniprot.org/uniprot/?querycandidalusitaniae&sortscore. These protein
sequences were used as protein evidence during structural annotations. We used MAKER (44) that
incorporates SNAP (45) into the gene prediction pipeline to annotate the P1 genome assembly. SNAP
gene predictions make use of hidden Markov models (HMMs) as their underlying probabilistic model.
Repetitive elements, including low-complexity sequences and interspersed repeats in the input genome
sequence, were identiﬁed and masked using RepeatMasker (46) by aligning the nonannotated genome
against a library of known repeats, such as Repbase (47). Transcript assemblies and protein sequences
described above were used as evidence to aid gene predictions. In the initial run, MAKER was launched
iteratively, and the tasks such as repeat masking and evidence alignments were performed, which
resulted in a general feature format 3 (GFF3) ﬁle containing the masked regions and protein transcript
alignments. The GFF3 ﬁle generated from the above-mentioned step was used during subsequent
MAKER runs. The data generated in the initial run were used in training the gene predictions using SNAP.
All the transcript sequences that were used as evidence during the initial MAKER run were placed into
a single transcript fasta ﬁle and were used for SNAP HMM training. After training SNAP HMMs from
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iterative runs that generate imperfect gene models, MAKER was run once again in the ﬁnal step to
accurately predict genes and corresponding ORFs.
Following the detection of ORFs, all proteins of the P1 genome were subjected to a BLAST search to
the Swiss-Prot database (release-2017_09) using Blast2GO (version 5.2.5; BioBam Bioinformatics, Valencia,
Spain). Top hits were retrieved from the BLAST results (E value cutoff, 103) and were added to each ORF
annotation. ORFs without BLAST results were resubmitted using Blast2GO to the nonredundant protein
NCBI database to enlarge the BLAST search, and positive results were added to the existing annotations.
Genome comparisons. Annotated genomes were compared using Mauve (version 2015-02-25), with
default parameters, and the aligner software Muscle 3.6. The produced alignments were next imported
in Geneious Prime (2019.1.3; Biomatters, Ltd., Auckland, New Zealand), and each chromosome alignment
was exported as a nucleotide alignment ﬁle. After establishing genome of isolate P1 as a reference, SNPs
and insertions/deletions were obtained by the software by selection of coding and noncoding regions.
SNP densities along chromosomes were obtained from VCF ﬁles extracted from each chromosome
comparison using Geneious. VCF ﬁles corresponding to each chromosome were imported into the online
software SNiPlay (48) with a size of the sliding window of 2,000 nucleotides. Data were exported in Prism
8.1.2 (GraphPad Software, San Diego, CA, USA) for visualization.
For P1 to P5 genome comparisons, differences between genomes in homopolymeric regions
[poly(dN) stretches of at least 7 nucleotides] were ignored since they were likely due to artifacts of the
PacBio sequencing technology, as reported earlier (49). Only differences in these stretches occurring in
at least 2 separate genomes were considered in genome comparisons. In addition, only telomeric
chromosome regions that were common to all P1 to P5 isolates were included in genome comparisons.
Genome-wide transcriptional analysis. (i) RNA extraction and processing. RNA was isolated from
5-ml log-phase cultures of isolates P1, P3, and P4 grown in YEPD medium at 30°C under agitation. Total
RNA was extracted from with the RNeasy Protect minikit (Qiagen) by a process involving mechanical
disruption of the cells with glass beads, as previously described (50). Total RNA extracts were treated with
DNase using a DNA-free kit (Ambion-Life Technologies, Zug, Switzerland). RNA quality and integrity were
veriﬁed with a fragment analyzer automated capillary electrophoresis (CE) system (Advanced Analytical).
RNA extractions were performed in biological triplicate. RNA libraries for RNA-seq were prepared with a
TruSeq stranded total RNA library prep kit (Illumina). The resulting libraries were sequenced on an
Illumina HiSeq 2500 system at the LGTF.
(ii) Quality control and processing of raw RNA-seq reads. Twenty-seven single-end RNA-seq data
sets from three different C. lusitaniae strains (P1, P3, and P4) after RNA sequencing were obtained. The
quality of the raw reads was assessed using FastQC (v0.11.7) (51). Prior to mapping and assembly, adapter
trimming, quality ﬁltering, artefact removal, and contaminant ﬁltering were carried out with BBDuk
(v38.51) from the BBTools package (52). Low-complexity ﬁltering and removal of rRNA sequences were
carried out using Prinseq (v0.20.3) (53) and SortMeRNA (v2.1) (54), respectively. The processed reads were
aligned to the P1 annotated genome using HSAT2 (v2.1) (55).
(iii) Differential gene expression analysis. Data normalization and differential expression analysis
were performed in R (v3.5.2) using the Bioconductor packages. The read count data were normalized
with the TMM (trimmed mean of M-values) method available in the R Bioconductor package edgeR (56)
and subsequently transformed to log2 counts per million by voom, a method implemented in the R
Bioconductor package limma (57). A linear model with one factor per condition was applied to the
transformed data using limma (58).
MRR1/MFS7 gene deletions. (i) Plasmid constructions. In order to delete MRR1 and MFS7 in C.
lusitaniae, the ﬂanking regions of the two genes were cloned by PCR into pSFS2A (59). MRR1 ﬂanking
regions were ampliﬁed from isolate P1 with the primer pairs ClMRR1-Apa/ClMRR1-Xho and ClMRR-SacI/
ClMRR-SacII (Table S1). MFS7 ﬂanking regions were ampliﬁed from isolate P1 with the primer pairs
MFS7-Kpn/MSF7-Xho and MFS7-SacI/MFS7-SacII (Table S1). PCR products were cloned sequentially into
corresponding sites to result in plasmid pDS1860 (MFS7 inactivation) and pDS1864 (MRR1 inactivation).
pDS1860 and pDS1864 were next modiﬁed by removing the SAT1 ﬂipper cassette system by BamHI/NotI
digestion and replacement with the NAT1 dominant marker ampliﬁed from pJK795 (60) using primers
NAT1-BglII and NAT1-Not, thus resulting in pDS2039 and pSD2038, respectively.
(ii) Cas9-CRISPR for knockout of MRR1 and MFS7. The RNA-protein complex (RNP) approach
reported by Grahl et al. (61) was used that employs reconstituted puriﬁed Cas9 protein in complex with
scaffold and gene-speciﬁc guide RNAs. Genomic RNA (gRNA) speciﬁc for MRR1 and MFS7 (Table S1) were
selected and obtained from Integrated DNA Technologies, Inc. (IDT) as CRISPR guide RNA (crRNA), which
contains 20 bp homologous to the target gene fused to the scaffold sequence. Gene-speciﬁc RNA guides
were designed in silico using Geneious Prime. RNPs were created using the Alt-R CRISPR-Cas9 system
from IDT. Brieﬂy, crRNAs (crMRR1 and crMFS7, Table S1) and tracrRNA (a universal transactivating CRISPR
RNA) were ﬁrst dissolved in RNase-free distilled water (dH2O) at 100 M and stored at –80°C. The
complete guide RNA was generated by mixing equimolar concentrations (4 M ﬁnal) of the gene-speciﬁc
crRNA and tracrRNA to obtain a ﬁnal volume of 3.6 l per transformation. The mix was incubated at 95°C
for 5 min and cool down to room temperature. The Cas9 nuclease 3NLS (60 M stock from IDT) was
diluted to 4 M in dH2O at a volume of 3 l per transformation. RNPs were assembled by mixing guide
RNAs (3.6 l of gene-speciﬁc crRNA/tracrRNA) with 3 l of diluted Cas9 protein, followed by incubation
at room temperature for 5 min. Transformation of C. lusitaniae cells was carried out by electroporation
and used 6.6 l of gene-speciﬁc RNPs, 40 l of C. lusitaniae cells, and 1 to 2 g of repair constructs (up
to 3.4 l volume). Repair constructs containing the MRR1 and MFS7 inactivation cassettes were obtained
by PCR ampliﬁcation with primer pairs ClMRR1-Apa/ClMRR-SacI and MFS7-Kpn/MFS7-SacI from pDS2038
and pSD2039, respectively. Transformants were selected at 30°C on YEPD agar containing 200 g/ml
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nourseothricin. Transformants were veriﬁed by PCR using the primer pair NAT1_134_R/ClMRR1-verif3 for
MRR1 deletion and NAT1_134_R/5-MFS7-A for MFS7 deletion. DNA from transformants was prepared by
small-scale rapid DNA extraction, as described previously (62).
(iii) MRR1 reversion. In order to reintroduce MRR1 alleles in the background of MRR1 deletion
mutants, an alternative mutant construction using a recyclable NAT1 marker was employed. The
maltose-inducible MAL2-FLP1 system of pSFS2A was ﬁrst excised from pSFS2A as a 0.9-kb ApaI-EcoRV
fragment and cloned into pJK863 to substitute the SAP2 promoter, thus resulting in pDS2046. In this
approach, the NAT1 marker could be recycled by MAL2-dependent FLP1 expression (MAL2-FLP-NAT1).
This plasmid was used as the PCR template with the primer pair MRR1-5_pDS2046/MRR1-3_pDS2046.
Both primers contained 70-bp homology to the MRR1 5=- and 3=-ﬂanking regions and a 21-bp extension
matching to the MAL2-FLP-NAT1 extremities. CRISPR-Cas9-mediated recombinations at MRR1 ﬂanking
regions with this PCR-ampliﬁed repair fragment were used with crRNAs crMRR1_del5 and crMRR1_del3
that were prepared as explained above to reconstitute functional RNPs, with the exception that both
RNPs were concentrated by 2-fold. Transformation of C. lusitaniae was carried out by electroporation, as
described below, and transformants were selected onto YEPD plates with nourseothricin (200 g/ml).
After MRR1 deletion veriﬁcation by PCR, as described above, strains were grown overnight on YEP
liquid medium with 2% maltose at 30°C in order to induce FLP1-mediated recombination at FLP
recombination target (FRT) sequences and the resulting loss of NAT1. Recycling of NAT1 was observed in
YEPD agar medium containing each about 102 C. lusitaniae cells at a nourseothricin concentration of
1 g/ml to distinguish between parent cells and those without NAT1.
Nourseothricin-sensitive C. lusitaniae cells deleted for MRR1 were used for MRR1 reversion. MRR1
alleles were ﬁrst cloned into pSD2038 with fragments obtained by PCR using primers ClMRR1-Apa and
ClMRR1-Xhorev and DNA templates from isolates P1 and P3, which resulted in plasmids pDS2040 and
pDS2041, respectively. Repair fragments were obtained from both plasmids with primers ClMRR1-Apa
and MRR1-3_rev_new. CRISPR-Cas9-mediated recombinations at the MRR1 ﬂanking regions with these
PCR-ampliﬁed repair fragments were used with crRNAs crRNA_MRR1_rev5 and crRNA_MRR1_rev3 that
were prepared as described above to reconstitute functional RNPs. Transformations of C. lusitaniae were
carried out by electroporation, as described below, and transformants were selected onto YEPD plates
with nourseothricin (200 g/ml). Reintegration ofMRR1 alleles was veriﬁed by PCR on recovered genomic
DNAwith the primer pair ClMRR1_F/ClMRR1_3377_R, followed by sequencing with primer ClMRR1_2900_F to
conﬁrm allele identity.
MFS7-GFP tagging. GFP tagging of MFS7 was realized by a Gateway cloning approach developed
by Chauvel et al. (63). MFS7 was ﬁrst ampliﬁed with the primers Forward_gateway_MFS7 and
Reverse_gateway_MFS7 (Table S1) and cloned into pDONR207 (63) by a recombination reaction with
Invitrogen Gateway BP Clonase. Next, MFS7 was transferred into pCA-DEST1102 (a plasmid aimed to
express C-terminal GFP fusion proteins under the control of a tetracycline-regulated promoter) by LR
Clonase resulting in pDS2034. Next, this plasmid was linearized by i-SceI and transformed for Ura
selection in strain CPY41, a derivative of SC5314 containing pNIMX (63) and lacking URA3 alleles, to yield
DSY5194.
MFS7 overexpression. MFS7 overexpression used a system that overexpresses proteins in C. albicans
through a CDR1 promoter under the control of a TAC1 gain-of-function allele (25). The MFS7 ORF was
ampliﬁed from isolate P1 with primers MFS7_XbaI and MFS7_Nhe and cloned into the single SpeI site of
pDS1873, a derivative of pDS1874 lacking CDR1-GFP (25), to yield pDS2022. This plasmid was digested
by SacI and PvuI to allow recombination at the CDR1 locus and transformed into DSY4684 lacking major
multidrug transporters (25). As control, DSY4684 was transformed with CIp10 after StuI digestion (64).
Transformants were obtained by Ura selection.
ERG3 and ERG4 reversions. In order to restore wild-type copies of ERG3 and ERG4 in isolates with
defects in these genes, a CRISPR approach was used. First, repair fragments were constructed by fusion
PCR. The ERG4 repair fragment was generated by fusion of three PCR fragments with overlapping
sequences. The ﬁrst PCR fragment ampliﬁed the wild-type ERG4 from isolate P1 with primers ERG4-P1
and ERG4-NAT1-R (20-bp overlap with pJK795 [60]). The second PCR fragment ampliﬁed the selective
marker NAT1 from pJK795 with primers ERG4-NAT1-F (20-bp overlap with ERG4) and ERG4-NAT1t-R
(20-bp overlap with pJK795). The third PCR fragment ampliﬁed a 3=-end portion of ERG4 with primers
ERG4-P2 and ERG4-NAT1t-F (20-bp overlap with pJK795). The ﬁnal PCR was performed with the 3 puriﬁed
fragments and nested primers ERG4-P3 and ERG4-P4 in the presence of 1.2 M betaine. The ERG3
repair fragment was constructed in a similar fashion but using the hygromycin resistance selection
marker from pYM70 (65). The ﬁrst PCR fragment ampliﬁed the wild-type ERG3 from isolate P1 with
primers ERG3-P1 and ERG3-HYG-R (20-bp overlap with pYM70). The second PCR fragment ampliﬁed
the selective marker CaHygB from pYM70 with primers ERG3-HYG-F (20-bp overlap with ERG3) and
ERG3-HYGt-R (20-bp overlap with pYM70). The third PCR fragment ampliﬁed a 3=-end portion of
ERG3 with primers ERG3-P2 and ERG3-HYGt-F (20-bp overlap with pJK795). The ﬁnal PCR was
performed with the 3 puriﬁed fragments and nested primers ERG3-P3 and ERG3-P4 in the presence
of 1.2 M betaine.
RNPs were reconstituted as described above. gRNA speciﬁc for ERG3 and ERG4 (Table S1) was
selected for targeting the mutated positions in isolates P2 and P5 and were obtained from Integrated
DNA Technologies, Inc. (IDT) as CRISPR guide RNA (crRNA) fused to the scaffold sequence. RNPs were
assembled by mixing guide RNAs (3.6 l of gene-speciﬁc crRNA/tracrRNA) with 3 l of diluted Cas9
protein, followed by incubation at room temperature for 5 min. Transformation of C. lusitaniae cells was
carried out by electroporation as described below and used 6.6 l of gene-speciﬁc RNPs, 40 l of C.
lusitaniae cells, and 1 to 2 g of ERG3 or ERG4 repair constructs (up to 3.4 l volume). Isolates P2 and P5
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were used with the ERG4 repair fragment, and transformant selection was operated onto nourseothricin-
selective medium (200 g/ml nourseothricin). The ERG3 repair fragment was used with an ERG4 revertant
from P5 and transformant selection was operated on hygromycin-selective medium (250 g/ml hygro-
mycin).
Veriﬁcation of ERG3 and ERG4 reversions was carried out by PCR with primers ClERG4_1427_F and
NAT1_134_R (ERG4) and primers ClERG3_1104_F and ERG3-HYG-R (ERG3), followed by sequencing.
C. lusitaniae transformation. Transformations in C. lusitaniae were carried out by electroporation.
Overnight-grown cells were freshly diluted 20-fold in 20 ml YEPD medium and grown to logarithmic
phase to a density of 1  107 to 2  107 cells/ml at 30°C under constant agitation. After centrifugation
for 5 min at 2,500 rpm at 4°C and removal of the supernatant, cells were resuspended in 10 ml
transformation buffer (100 mM lithium acetate [LiAc], 100 mM dithiothreitol [DTT], 10 mM Tris-HCl [pH
7.5], 1 mM EDTA) and incubated for 1 h at room temperature under mild shaking. Cells were next washed
twice with ice-cold water and with 1 M sorbitol. Cell pellets were ﬁnally resuspended in 200 l 1 M
sorbitol. Transformations were carried out with aliquots of 40 l of slurry in 0.2-cm electroporation
cuvettes (Bio-Rad) with the following settings: 1.8 kV, 200, and 25 F. After an electroporation pulse,
1 ml YEPD was immediately added, and cells were incubated overnight with gentle shaking at 30°C. Once
the cells were allowed to recover overnight at room temperature, aliquots were plated onto the
corresponding selective media.
Quantitative reverse transcription-PCR. Total RNA was extracted as described above from log-
phase cultures grown in YEPD at 30°C under constant agitation. Gene expression levels were determined
by real-time quantitative reverse transcription-PCR (qRT-PCR) in a StepOne real-time PCR system (Applied
Biosystems) using the Mesa Blue qPCR MasterMix Plus for SYBR assay kit (Eurogentec). Each reaction was
performed in triplicate on three separate occasions. Expression levels of MFS7 were normalized by ACT1
expression, as described previously (7).
Sterol analysis. Overnight cultures of C. lusitaniae strains were used to inoculate 10 ml YEPD at a
starting concentration of 1 104 cells/ml. Cultures were grown for 18 h at 37°C and 200 rpm. Cells were
then harvested and pellets washed twice with double-distilled water (ddH2O). Sterols were extracted and
derivatized as previously described (66). Brieﬂy, lipids were saponiﬁed using alcoholic KOH and nonsa-
poniﬁable lipids extracted with hexane. Samples were dried in a vacuum centrifuge and were derivatized
by the addition of 0.1 ml BSTFA [N,O-Bis(trimethylsilyl)triﬂuoroacetamide] and trimethylchlorosilane
(TMCS) (99:1; Sigma) and 0.3 ml anhydrous pyridine (Sigma) and heated at 80°C for 2 h. TMS-derivatized
sterols were analyzed and identiﬁed using gas chromatography-mass spectrometry (GC/MS) (Thermo
1300 GC coupled to a Thermo ISQ mass spectrometer; Thermo Scientiﬁc) and the Xcalibur software
(Thermo Scientiﬁc). The retention times and fragmentation spectra for known standards were used to
identify sterols.
Virulence assays with Galleria mellonella. Galleria mellonella larvae were purchased from TruLarv
(Biosystems Technology, Exeter, Devon, UK). Larvae weighing between 0.2 and 0.3 g were selected for
our experiments and stored at 16°C upon arrival. A total of 10 larvae were infected with each isolate by
microinjection (Omnican100; BBraun). C. lusitaniae cells were grown overnight in YEPD medium at 30°C
under agitation and pelleted by centrifugation (5 min at 4,600 rpm). Cells were washed twice with
phosphate-buffered saline (PBS; 137 mM NaCl, 10 mM phosphate, 2.7 mM KCl [pH 7.4]), and the amount
of cells was estimated with a photometer (Novaspec II; Pharmacia). Forty microliters of a cell suspension
containing 1.5 107 cells/ml in PBS was then injected into the last left proleg. Control larvae were
injected with the same volume of PBS. The injected larvae were incubated at 30°C in the dark for 9 days
postinfection, and survival was scored each day. Larvae were scored as dead when melanized and upon
lack of response after gentle manipulation with a clamp.
Microscopy. Epiﬂuorescence and phase-contrast imaging were performed with a Zeiss Axioplan 2
microscope equipped for epiﬂuorescence microscopy with a 100-W mercury high-pressure bulb and
Zeiss ﬁlter set 9 (for GFP imaging). Images obtained with a SPOT RT3 cooled 2 Mp charge-coupled-device
(CCD) camera (Diagnostic Instruments, Inc., MI, USA) were recorded and captured with VisiView (Visitron
Systems GmbH, Germany).
Data availability. Strains described here are available upon request. PacBio assemblies are available
under BioProject number PRJNA504391. RNA-seq data are available under study number SRP172837. The
ﬁnal assembled genomes for isolates P1 to P5 and their annotations are available under accession
numbers CP038484 to CP038491, CP039550 to CP039557, CP039652 to CP039659, CP039618 to
CP039625, and CP039660 to CP039667, respectively.
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